A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study-Reference-Cited by-同舟云学术

A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study

Published:2016-10-21 Issue:3 Volume:46 Page:236-240
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Chiu Y-M¹²,Tang C-H³,Hung S-T⁴,Yang Y-W⁵,Fang C-H⁵,Lin H-Y⁶⁷

Affiliation:

1. Division of Allergy, Immunology and Rheumatology, Changhua Christian Hospital, Changhua, Taiwan

2. Department of Nursing, College of Medicine and Nursing, HungKuang University, Taichung, Taiwan

3. School of Health Care Administration, Taipei Medical University, Taipei, Taiwan

4. Formosa Biomedical Technology Corporation, Taipei, Taiwan

5. Pfizer Limited, Taipei, Taiwan

6. Division of Allergy, Immunology and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

7. Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan

Funder

Pfizer Ltd.

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2016.1202318

Reference39 articles.

1. Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

2. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy

3. Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy

4. Antirheumatic Drugs and the Risk of Tuberculosis

5. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review;Frontiers in Pharmacology;2023-01-20

2. Reply to: “Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab” by Josef Finsterer;Reumatismo;2022-05-03

3. Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab;Reumatismo;2022-05-03

4. Rheumatoid arthritis management in the APLAR region: Perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases;International Journal of Rheumatic Diseases;2021-08-10

5. Risk of herpes zoster in psoriasis patients receiving systemic therapies: a nationwide population-based cohort study;Scientific Reports;2021-06-03